Article
A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers.
PloS one - 1 Jan 2013
Lee Jeeyun, Kim Sung, Kim Phillip, Liu Xinjun, Lee Tani, Kim Kyoung-Mee, Do In-Gu, Park Joon Oh, Park Se Hoon, Jang Jiryeon, Hoe Nicholas, Harvie Gulia, Kuller Anne, Jain Anjali, Meyer Gary, Leesman Glen, Park Young Suk, Choi Min Gew, Sohn Tae Sung, Bae Jae Moon, Lim Ho Yeong, Singh Sharat, Kang Won Ki
Abstract excerpt
PURPOSE: The aim of this study was to utilize the proteomics-based Collaborative Enzyme Enhanced Reactive (CEER) immunoassay to investigate protein tyrosine phosphorylations as diagnostic markers in gastric cancers (GCs). EXPERIMENTAL DESIGN: Protein lysates from fresh-frozen 434 advanced stage GCs were analyzed for phosphorylation of HER1, HER2, p95HER2, HER3, cMET, IGF1R and PI3K. The pathway activation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.